179 related articles for article (PubMed ID: 32049841)
1. Clinical efficacy and safety of imatinib treatment in children and adolescents with chronic myeloid leukemia: A single-center experience in China.
Deng M; Guan X; Wen X; Xiao J; An X; Yu J
Medicine (Baltimore); 2020 Feb; 99(7):e19150. PubMed ID: 32049841
[TBL] [Abstract][Full Text] [Related]
2. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
3. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China.
Cai Y; Liu C; Guo Y; Chen X; Zhang L; Chen Y; Zou Y; Yang W; Zhu X
Int J Hematol; 2021 Mar; 113(3):413-421. PubMed ID: 33386594
[TBL] [Abstract][Full Text] [Related]
5. A Retrospective Study of Clinical Profile and Long Term Outcome to Imatinib Mesylate Alone in Childhood Chronic Myeloid Leukemia in Chronic Phase.
Department of Medical and Pediatric Oncology, The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat. INDIA
Gulf J Oncolog; 2017 Jan; 1(23):15-20. PubMed ID: 28271997
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.
Gore L; Kearns PR; de Martino ML; Lee ; De Souza CA; Bertrand Y; Hijiya N; Stork LC; Chung NG; Cardos RC; Saikia T; Fagioli F; Seo JJ; Landman-Parker J; Lancaster D; Place AE; Rabin KR; Sacchi M; Swanink R; Zwaan CM
J Clin Oncol; 2018 May; 36(13):1330-1338. PubMed ID: 29498925
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
Dou XL; Yu L; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):924-931. PubMed ID: 31856442
[No Abstract] [Full Text] [Related]
8. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
Suttorp M; Schulze P; Glauche I; Göhring G; von Neuhoff N; Metzler M; Sedlacek P; de Bont ESJM; Balduzzi A; Lausen B; Aleinikova O; Sufliarska S; Henze G; Strauss G; Eggert A; Kremens B; Groll AH; Berthold F; Klein C; Groß-Wieltsch U; Sykora KW; Borkhardt A; Kulozik AE; Schrappe M; Nowasz C; Krumbholz M; Tauer JT; Claviez A; Harbott J; Kreipe HH; Schlegelberger B; Thiede C
Leukemia; 2018 Jul; 32(7):1657-1669. PubMed ID: 29925908
[TBL] [Abstract][Full Text] [Related]
9. Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response.
Ferreira APS; Seguro FS; Abdo ARN; Santos FM; Maciel FVR; Nardinelli L; Giorgi RR; Ruiz ARL; Ferreira MPS; Rego EM; Rocha V; Bendit I
Ann Hematol; 2023 Jul; 102(7):1761-1771. PubMed ID: 37052662
[TBL] [Abstract][Full Text] [Related]
10. Five-year follow-up of patients treated with imatinib mesylate for chronic myeloid leukaemia in Trinidad and Tobago.
Charles KS; Ramon L; Leelah N; Oluwabusi TA; Seemungal T
West Indian Med J; 2011 Jun; 60(3):298-302. PubMed ID: 22224342
[TBL] [Abstract][Full Text] [Related]
11. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
12. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
[TBL] [Abstract][Full Text] [Related]
13. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
[TBL] [Abstract][Full Text] [Related]
14. The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China.
Shao H; Zeng Z; Cen J; Zhang J; Bai S; Wu C; Gong Y; Wang Y; Qiu H; Chen S; Pan J
Leuk Lymphoma; 2018 Sep; 59(9):2152-2158. PubMed ID: 29334300
[TBL] [Abstract][Full Text] [Related]
15. [Imatinib is effective in a 12-month-old boy with chronic myelogenous leukemia: case report and literature review].
Pan Y; Wen S; Tian J; Lyu Z; Du Z; Yan L
Zhonghua Er Ke Za Zhi; 2015 Mar; 53(3):194-7. PubMed ID: 26165016
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of generic and original imatinib in the treatment of newly diagnosed patients with chronic myelogenous leukemia in chronic phase: a multicenter retrospective clinical study].
Jiang H; Zhi LT; Hou M; Wang JX; Wu DP; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2017 Jul; 38(7):566-571. PubMed ID: 28810322
[No Abstract] [Full Text] [Related]
18. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Sawyers CL; Hochhaus A; Feldman E; Goldman JM; Miller CB; Ottmann OG; Schiffer CA; Talpaz M; Guilhot F; Deininger MW; Fischer T; O'Brien SG; Stone RM; Gambacorti-Passerini CB; Russell NH; Reiffers JJ; Shea TC; Chapuis B; Coutre S; Tura S; Morra E; Larson RA; Saven A; Peschel C; Gratwohl A; Mandelli F; Ben-Am M; Gathmann I; Capdeville R; Paquette RL; Druker BJ
Blood; 2002 May; 99(10):3530-9. PubMed ID: 11986204
[TBL] [Abstract][Full Text] [Related]
19. [A retrospective analysis of the efficacy and safety of imatinib in children with chronic myeloid leukemia during chronic phase].
Zhang LQ; Zheng J; Chen ZP; Li SD; Ma J; Wu RH
Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):113-117. PubMed ID: 30695885
[No Abstract] [Full Text] [Related]
20. [A comparison of efficacy and safety between Chinese generic imatinib versus branded imatinib in patients with newly-diagnosed chronic myeloid leukemia in the chronic phase: a single-center prospective cohort study].
Shi HX; Qin YZ; Lai YY; Huang XJ; Jiang Q
Zhonghua Nei Ke Za Zhi; 2016 Dec; 55(12):922-926. PubMed ID: 27916045
[No Abstract] [Full Text] [Related]
[Next] [New Search]
